During the past decade, Rinku General Medical Center conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 5 clinical trials were completed, i.e. on average, 26.3% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 5 clinical trials were completed. i.e. 41.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rinku General Medical Center" #1 sponsor was "Pfizer" with 5 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rinku General Medical Center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 3 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Japan Blood Products Organization" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Rinku General Medical Center" are "COVID-19" (3 trials), "Colorectal Cancer" (3 trials), "Cervical Ripening" (2 trials), "Coronary Artery Disease" (2 trials) and "Covid19" (2 trials). Many other conditions were trialed in "Rinku General Medical Center" in a lesser frequency.

Most popular intervention types in "Rinku General Medical Center" are "Drug" (24 trials), "Device" (6 trials), "Biological" (3 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Dinoprostone" (2 trials), "PF-07321332" (2 trials), "Ritonavir" (2 trials) and "UFT adjuvant chemotherapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rinku General Medical Center" are 29 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Rinku General Medical Center". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Rinku General Medical Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rinku General Medical Center, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".